Dose-dense mini-CVD in combination with inotuzumab and blinatumomab leads to early and high overall rates of deep MRD negativity by NGS of 95% (44% post C1) with a 3-year OS rate of 80%…

Dr. Gabriela Hobbs offers her top poster recommendations in myeloproliferative neoplasms presented at the SOHO 2026 Annual Meeting, which include data on a mutant calreticulin-specific antibody in…

Click here to visit the conference website

Treatment strategies and survival outcomes substantially differed between patients with low-risk versus high-risk myelodysplastic syndromes (MDS), according to an analysis of the Spanish Registry of…

Patients with telomere biology disorders (TBDs) exhibited substantial hematologic and multiorgan morbidity as well as frequent clonal hematopoiesis with a high rate of PPM1D and U2AF1 mutations,…

The roundtable panelists discuss where CELMoDs, including mezigdomide and iberdomide, fit in the multiple myeloma treatment landscape. The panel evaluates the distinct toxicity profiles of these…

Olverembatinib, a third-generation BCR::ABL1 tyrosine kinase inhibitor, plus blinatumomab demonstrated promising efficacy and manageable safety for patients with relapsed or refractory Philadelphia…

The first- and second-generation immunomodulatory drugs (IMiDs) have fundamentally transformed the treatment landscape of multiple myeloma (MM) over the past two decades. Lenalidomide combinations…

Guillermo García-Manero, MD, professor and chief of the Section of Myelodysplastic Syndromes and ad interim chair of the Department of Leukemia at the University of Texas MD Anderson Cancer Center,…

Severe aplastic anemia (SAA) remains one of the most consequential non-malignant hematologic disorders, defined by profound bone marrow failure and life-threatening cytopenias. Although technically…

A study found that baseline platelet count, ASXL1 mutation, and Revised International Prognostic Scoring System (IPSS-R) status were the most important predictors of response to imetelstat in…

Ofirnoflast, a first-in-class allosteric NEK7 inhibitor, showed favorable safety and clinically significant efficacy in patients with low-risk myelodysplastic syndromes (LR-MDS) refractory to…